ORMP
Oramed Pharmaceuticals Inc.NASDAQHealthcare$3.42+0.88%ClosedMarket Cap: $138.3M
As of 2026-04-06
Valuation
P/E (TTM)
1.84
PEG
0.00
P/B
0.71
P/S
69.57
EV/EBITDA
-6.23
DCF Value
$1.07
FCF Yield
-9.4%
Div Yield
7.3%
Margins & Returns
Gross Margin
0.7%
Operating Margin
-754.4%
Net Margin
3766.2%
ROE
43.1%
ROA
77.2%
ROIC
-19.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-5.7M | $21.3M | $0.25 | — |
| FY 2025 | $2.0M | 0.7% | $-15.1M | $75.3M | $1.50 | — |
| Q3 2025 | $0.00 | -Infinity% | $-2.4M | $48.4M | $1.13 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.5M | $13.3M | $0.31 | — |
| Q1 2025 | $2.0M | 0.7% | $-4.5M | $-7.6M | $-0.19 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.6M | $-10.2M | $-0.26 | — |
| FY 2024 | $0.00 | -Infinity% | $-12.8M | $-19.1M | $-0.47 | — |
| Q3 2024 | $0.00 | NaN% | $-3.1M | $-19.6M | $-0.48 | — |
| Q2 2024 | $0.00 | NaN% | $-3.1M | $9.2M | $0.22 | — |
| Q1 2024 | $0.00 | NaN% | $-3.0M | $1.5M | $0.04 | — |
| Q4 2023 | $0.00 | NaN% | $-3.9M | $13.3M | $0.33 | — |
| FY 2023 | $1.3M | 100.0% | $-15.8M | $5.5M | $0.14 | — |